Study to Assess the Safety and Effectiveness of NMRA-335140-501
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Depressive Disorder
2 other identifiers
interventional
1,000
11 countries
178
Brief Summary
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 major-depressive-disorder
Started Nov 2023
Longer than P75 for phase_3 major-depressive-disorder
178 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 1, 2023
CompletedFirst Posted
Study publicly available on registry
September 8, 2023
CompletedStudy Start
First participant enrolled
November 10, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
April 8, 2026
April 1, 2026
3.6 years
September 1, 2023
April 7, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Safety and tolerability assessments based on Treatment Emergent Adverse Events (TEAEs) and validated clinical scales
An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). Clinically significant abnormalities in Clinical Laboratory Evaluations, ECGs, Vital Signs, Physical and Ophthalmological examinations, Corneal Specular Microscopy, Columbia Suicide Severity Rating Scale (C-SSRS), and Sexual Functioning Questionnaire-14 (CSFQ-14) will be reported as TEAEs.
Up to 54 Weeks
Secondary Outcomes (10)
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time.
Baseline and up to Week 54
Change from Baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score over time
Baseline and up to Week 54
Change from Baseline in the Patient Health Questionnaire-9 (PHQ-9) total score over time.
Baseline and up to Week 54
Change from Baseline in PHQ-9 Anhedonia Item #1 over time.
Baseline and up to Week 54
Change from Baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score over time.
Baseline and up to Week 54
- +5 more secondary outcomes
Study Arms (1)
NMRA-335140 80 milligrams (mg) once daily (QD)
EXPERIMENTALParticipants will receive a NMRA-335140 tablet at a dose of 80 mg once daily (QD) during a 52-week treatment period.
Interventions
Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
Eligibility Criteria
You may qualify if:
- Completed a previous NMRA-335140 Phase 3 MDD study (example: NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303) according to the completion definition in the parent study protocol.
- Signed an informed consent form (ICF) for this study.
You may not qualify if:
- Considered to be at significant risk of suicide in the judgment of the Investigator. This includes participants who are actively suicidal (eg, any suicide attempts during the parent study) or are at serious suicidal risk as indicated by any current suicidal intent, including a plan, as assessed by the C-SSRS ("Since Last Visit" version, score of "YES" on suicidal ideation Item 4 or 5) and/or based on clinical evaluation by the Investigator; or are homicidal, in the opinion of the Investigator.
- Non-adherent with study medication (took ≤70% of study drug over any 2-week visit interval) or procedures during the parent study.
- Experienced treatment emergent adverse events (TEAEs) considered related to the study medication from the parent study and judged by the Investigator to be clinically significant to render the participant ineligible for enrollment.
- Have an abnormality on ocular examination that would prohibit continued study participation as determined by the Investigator.
- Considered by the Investigator to be inappropriate for any other reason.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (178)
Neumora Investigator site
Huntsville, Alabama, 35801, United States
Neumora Investigator Site
Phoenix, Arizona, 85012, United States
Neumora Investigator Site
Bentonville, Arkansas, 72712, United States
Neumora Investigator Site #1
Little Rock, Arkansas, 72211, United States
Neumora Investigator site
Little Rock, Arkansas, 72211, United States
Neumora Investigator Site
Rogers, Arkansas, 72758, United States
Neumora Investigator site
Bellflower, California, 90706, United States
Neumora Investigator Site
Cerritos, California, 90703, United States
Neumora Investigator Site
Encino, California, 91316, United States
Neumora Investigator Site
Garden Grove, California, 92845, United States
Neumora Investigator Site
Glendale, California, 91206, United States
Neumora Investigator Site
Imperial, California, 92251, United States
Neumora Investigator Site
Irvine, California, 92614, United States
Neumora Investigator Site
Lafayette, California, 94549, United States
Neumora Investigator Site #1
Long Beach, California, 90807, United States
Neumora Investigator site
Long Beach, California, 90807, United States
Neumora Investigator Site
Los Angeles, California, 90015, United States
Neumora Investigator Site
Newport Beach, California, 92660, United States
Neumora Investigator Site
Oceanside, California, 92056, United States
Neumora Investigator Site #1
Orange, California, 92868, United States
Neumora Investigator Site
Orange, California, 92868, United States
Neumora Investigator Site
Riverside, California, 92506, United States
Neumora Investigator Site
San Diego, California, 92103, United States
Neumora Investigator Site
San Francisco, California, 94107, United States
Neumora Investigator Site
San Jose, California, 95124, United States
Neumora Investigator Site
Santa Ana, California, 92704, United States
Neumora Investigator Site
Sherman Oaks, California, 91403, United States
Neumora Investigator Site
Temecula, California, 92591, United States
Neumora Investigator Site
Torrance, California, 90504, United States
Neumora Investigator Site
Colorado Springs, Colorado, 80910, United States
Neumora Investigator Site
New Haven, Connecticut, 06520, United States
Neumora Investigator Site
Norwalk, Connecticut, 06851, United States
Neumora Investigator Site
Bradenton, Florida, 34205, United States
Neumora Investigator Site
Brandon, Florida, 33511, United States
Neumora Investigator Site
Gainesville, Florida, 32607, United States
Neumora Investigator Site
Hallandale, Florida, 33009, United States
Neumora Investigator Site
Hialeah, Florida, 33012, United States
Neumora Investigator Site
Hialeah, Florida, 33016, United States
Neumora Investigator Site
Hollywood, Florida, 33024, United States
Neumora Investigator Site
Jacksonville, Florida, 32256, United States
Neumora Investigator Site
Lauderhill, Florida, 33319, United States
Neumora Investigator Site
Maitland, Florida, 32751, United States
Neumora Investigator Site
Miami, Florida, 33122, United States
Neumora Investigator Site
Miami, Florida, 33126, United States
Neumora Investigator Site
Miami, Florida, 33133, United States
Neumora Investigator Site
Miami, Florida, 33137, United States
Neumora Investigator Site
Miami, Florida, 33143, United States
Neumora Investigator Site
Miami, Florida, 33165, United States
Neumora Investigator Site
Miami, Florida, 33174, United States
Neumora Investigator site
Miami, Florida, 33183, United States
Neumora Investigator Site
Miami Beach, Florida, 33140, United States
Neumora Investigator site
Miami Lakes, Florida, 33014, United States
Neumora Investigator Site #1
Miami Lakes, Florida, 33016, United States
Neumora Investigator Site #2
Miami Lakes, Florida, 33016, United States
Neumora Investigator Site
Miami Springs, Florida, 33166, United States
Neumora Investigator Site #1
Orlando, Florida, 32801, United States
Neumora Investigator site
Orlando, Florida, 32801, United States
Neumora Investigator Site
Orlando, Florida, 32803, United States
Neumora Investigator Site
Orlando, Florida, 32807, United States
Neumora Investigator Site
Pembroke Pines, Florida, 33024, United States
Neumora Investigator Site #1
Pompano Beach, Florida, 33060, United States
Neumora Investigator Site
Pompano Beach, Florida, 33060, United States
Neumora Investigator Site
Saint Augustine, Florida, 32086, United States
Neumora Investigator Site
Tampa, Florida, 33607, United States
Neumora Investigator Site #1
Tampa, Florida, 33613, United States
Neumora Investigator Site
Tampa, Florida, 33613, United States
Neumora Investigator Site
Atlanta, Georgia, 30318, United States
Neumora Investigator Site #1
Atlanta, Georgia, 30328, United States
Neumora Investigator Site
Atlanta, Georgia, 30328, United States
Neumora Investigator Site
Atlanta, Georgia, 30338, United States
Neumora Investigator Site
Decatur, Georgia, 30030, United States
Neumora Investigator Site
Marietta, Georgia, 30060, United States
Neumora Investigator Site
Savannah, Georgia, 31405, United States
Neumora Investigator Site
Chicago, Illinois, 60634, United States
Neumora Investigator Site
Warrenville, Illinois, 60555, United States
Neumora Investigator Site
Marrero, Louisiana, 70072, United States
Neumora Investigator Site
New Orleans, Louisiana, 70115, United States
Neumora Investigator Site
Baltimore, Maryland, 21208, United States
Neumora Investigator site
Towson, Maryland, 21204, United States
Neumora Investigator Site
Boston, Massachusetts, 02116, United States
Neumora Investigator Site
Boston, Massachusetts, 02131, United States
Neumora Investigator site
Methuen, Massachusetts, 01844, United States
Neumora Investigator site
Springfield, Massachusetts, 01103, United States
Neumora Investigator Site
Watertown, Massachusetts, 02472, United States
Neumora Investigator site
Bloomfield Township, Michigan, 48302, United States
Neumora Investigator Site
Mankato, Minnesota, 56001, United States
Neumora Investigator Site
Flowood, Mississippi, 39232, United States
Neumora Investigator Site
Saint Charles, Missouri, 63304, United States
Neumora Investigator Site
St Louis, Missouri, 63141, United States
Neumora Investigator Site
Las Vegas, Nevada, 89102, United States
Neumora Investigator Site
Berlin, New Jersey, 08009, United States
Neumora Investigator site
Princeton, New Jersey, 08540, United States
Neumora Investigator Site
Toms River, New Jersey, 08755, United States
Neumora Investigator Site
Albuquerque, New Mexico, 87109, United States
Neumora Investigator Site
Brooklyn, New York, 11224, United States
Neumora Investigator Site
Buffalo, New York, 14215, United States
Neumora Investigator Site
Cedarhurst, New York, 11516, United States
Neumora Investigator Site
Inwood, New York, 11096, United States
Neumora Investigator Site
New York, New York, 10017, United States
Neumora Investigator Site
New York, New York, 10029, United States
Neumora Investigator Site
New York, New York, 10036, United States
Neumora Investigator Site
Staten Island, New York, 10310, United States
Neumora Investigator Site
Staten Island, New York, 10314, United States
Neumora Investigator Site
The Bronx, New York, 10461, United States
Neumora Investigator Site
Charlotte, North Carolina, 28211, United States
Neumora Investigator Site
Monroe, North Carolina, 28112, United States
Neumora Investigator Site
Columbus, Ohio, 43210, United States
Neumora Investigator Site
Dayton, Ohio, 45417, United States
Neumora Investigator Site
North Canton, Ohio, 44720, United States
Neumora Investigator Site
Edmond, Oklahoma, 73013, United States
Neumora Investigator Site
Oklahoma City, Oklahoma, 73118, United States
Neumora Investigator Site
Allentown, Pennsylvania, 18104, United States
Neumora Investigator Site
Media, Pennsylvania, 19063, United States
Neumora Investigator Site
Philadelphia, Pennsylvania, 19104, United States
Neumora Investigator Site
Memphis, Tennessee, 38119, United States
Neumora Investigator Site
Austin, Texas, 78737, United States
Neumora Investigator site
Austin, Texas, 78759, United States
Neumora Investigator Site
Dallas, Texas, 75243, United States
Neumora Investigator Site
DeSoto, Texas, 75115, United States
Neumora Investigator Site
Fort Worth, Texas, 76104, United States
Neumora Investigator Site #1
Houston, Texas, 77030, United States
Neumora Investigator Site
Houston, Texas, 77030, United States
Neumora Investigator Site
Houston, Texas, 77090, United States
Neumora Investigator Site
Wichita Falls, Texas, 76309, United States
Neumora Investigator Site
Bellevue, Washington, 98007, United States
Neumora Investigator Site #1
Everett, Washington, 98201, United States
Neumora Investigator Site
Curitiba, Paraná, 80240280, Brazil
Neumora Investigator Site
Botafogo - Rio de Janeiro, Rio de Janeiro, 22270-060, Brazil
Neumora Investigator Site
Porto Alegre, Rio Grande do Sul, 90610-001, Brazil
Neumora Investigator Site
Santa Cecília, São Paulo, 01228-000, Brazil
Neumora Investigator Site
São Bernardo do Campo, São Paulo, 09726150, Brazil
Neumora Investigator Site
São José do Rio Preto, São Paulo, 15090-000, Brazil
Neumora Investigator Site
São Paulo, 01236030, Brazil
Neumora Investigator Site
Cherven Bryag, Pleven, 5980, Bulgaria
Neumora Investigator Site
Sofia, Sofia-Grad, 1408, Bulgaria
Neumora Investigator Site
Sofia, Sofia-Grad, 1463, Bulgaria
Neumora Investigator Site
Sofia, Sofia-Grad, 1680, Bulgaria
Neumora Investigator Site
Varosha, Targovishte, 7700, Bulgaria
Neumora Investigator Site
Kardzhali, 6600, Bulgaria
Neumora Investigator Site
Pleven, 5800, Bulgaria
Neumora Investigator Site
Varna, 9020, Bulgaria
Neumora Investigator Site
Kelowna, British Columbia, V1Y 1Z9, Canada
Neumora Investigator Site
Hamilton, Ontario, L8S 1B7, Canada
Neumora Investigator Site
Markham, Ontario, L3R 1A3, Canada
Neumora Investigator Site
Mississauga, Ontario, L5L 1W8, Canada
Neumora Investigator Site
Toronto, Ontario, M5S 1M2, Canada
Neumora Investigator Site
Santiago, Santiago Metropolitan, 7500710, Chile
Neumora Investigator Site
Santiago, Santiago Metropolitan, 7560356, Chile
Neumora Investigator Site
Santiago, Santiago Metropolitan, 7561282, Chile
Neumora Investigator Site
Santiago, Santiago Metropolitan, 8330034, Chile
Neumora Investigator Site
Antofagasta, 1270244, Chile
Neumora Investigator Site
Pilsen, Plzeň, 301 00, Czechia
Neumora Investigator Site
Prague, Prague, 186 00, Czechia
Neumora Investigator Site
Kladno, South Bohemian, 272 01, Czechia
Neumora Investigator Site
Kladno, 272 01, Czechia
Neumora Investigator Site
Prague, 109 00, Czechia
Neumora Investigator Site
Helsinki, Etelä-Suomen Lääni, 00100, Finland
Neumora Investigator Site
Turku, Etelä-Suomen Lääni, 20520, Finland
Neumora Investigator Site
Oulu, Oulun Lääni, 90100, Finland
Neumora Investigator Site
Clermont-Ferrand, Auvergne-Rhône-Alpes, 63000, France
Neumora Investigator Site
Douai, Hauts-de-France, 59500, France
Neumora Investigator Site
Montpellier, Hérault, 34295, France
Neumora Investigator Site
La Roche-sur-Yon, Vendée, 85000, France
Neumora Investigator Site
Poitiers, Vienne, 86000, France
Neumora Investigator Site #1
Berlin, 10117, Germany
Neumora Investigator Site
Berlin, 10117, Germany
Neumora Investigator Site
Berlin, 10629, Germany
Neumora Investigator Site
Berlin, 13187, Germany
Neumora Investigator Site
Hamburg, 20253, Germany
Neumora Investigator Site
Suchy Las, Greater Poland Voivodeship, 62-002, Poland
Neumora Investigator Site
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-133, Poland
Neumora Investigator Site
Wroclaw, Lower Silesian Voivodeship, 50-414, Poland
Neumora Investigator Site
Lublin, Lublin Voivodeship, 20-109, Poland
Neumora Investigator Site
Lublin, Lublin Voivodeship, 20-582, Poland
Neumora Investigator Site
Białystok, Podkarpackie Voivodeship, 15-879, Poland
Neumora Investigator Site
Gdansk, Pomeranian Voivodeship, 80-438, Poland
Neumora Investigator Site
Lund, Skåne County, 222 22, Sweden
Neumora Investigator Site
Stockholm, Stolkholm Ian, 113 29, Sweden
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 1, 2023
First Posted
September 8, 2023
Study Start
November 10, 2023
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2027
Last Updated
April 8, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share